Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
BCRX similar filings
- 4 Dec 20 BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
- 5 Nov 20 BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones
- 30 Sep 20 Regulation FD Disclosure
- 3 Sep 20 U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile
- 31 Aug 20 NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir
- 31 Aug 20 Regulation FD Disclosure
- 6 Aug 20 BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones
Filing view
External links
EXHIBIT 10.1